Tudor Investment Corp
TPST icon

Tudor Investment Corp’s Tempest Therapeutics TPST Stock Holding History

Tudor Investment Corp’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-45
Closed -$249K – 1376
2017
Q1 		$249K Sell
45
-71
-61% -$331K 0.01% 1109
2016
Q4 		$519K Buy
116
+106
+1,060% +$1.32M 0.01% 702
2016
Q3 		$210K Sell
10
-5
-33% -$90.5K ﹤0.01% 1231
2016
Q2 		$224K Buy
+15
New +$343K ﹤0.01% 1347

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tudor Investment Corp's TPST Position: Q2 2017 in Review

Tudor Investment Corp sold out of Tempest Therapeutics (TPST) in Q2 2017, closing a stake of 45 shares — an estimated $249K sold.

Tudor Investment Corp first reported a position in TPST in Q2 2016 and held it in 4 quarters. The position peaked at $519K in Q4 2016. 54 funds tracked by Wall St. Rank hold TPST as of Q2 2017.

  • Tudor Investment Corp reported no remaining Tempest Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Tudor Investment Corp sold 45 Tempest Therapeutics shares in Q2 2017, an estimated $249K.
  • Tudor Investment Corp first reported a position in Tempest Therapeutics in Q2 2016 and held it in 4 quarters.
  • Tudor Investment Corp's Tempest Therapeutics position peaked at $519K in Q4 2016.
  • 54 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2017.

Based on Tudor Investment Corp's 13F filing for Q2 2017, filed 14 Aug 2017.